PD-1 Variants with Enhanced PD-L1 Binding Affinity

摘要

The present invention relates to a PD-1 variant with increased PD-L1 binding ability. In addition, the present invention relates to a method for preparing and screening the PD-1 variant. The PD-1 mutant of the present invention effectively inhibits the binding between wild-type PD-1 and PD-L1, and is expected to have significantly higher permeability and cancer killing effect of immune cells or treatment effect of infectious diseases compared to conventional immune checkpoint inhibitory treatments. And, at the same time, the possibility of immunogenicity can be minimized. In addition, the convenience of biopharmaceutical development can be promoted through the implementation of sugar-free.